Answers are grounded in this paper and cite their sources.
The author argues that effective and safe fibrinolytic therapy requires both tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), mimicking natural fibrinolysis.
the fibrinolytic degradation product D-dimer in plasma (110-250 ng/ ml).Therapy with tPA alone was believed to the biological pathway.However, this idea represented a fundamental misunderstanding of the biological system, which remains to be addressed [1].Ever since the FDA approved tPA for the treatment of AMI I 1987, it has been the activator choice.However, the body has two plasminogen activators, the second one being urokinase Plasminogen Activator (uPA), the native form of which is a proenzyme (prouPA) [2].Since both are required for an effective and safe fibrinolytic effect, the full potential of fibrinolytic therapy has never been evaluated.
No takes yet. Share an insight, caveat, or question.
Victor Gurewich (2018) conducted a review in Acute Myocardial Infarction (AMI) (n=101). Sequential combination of tPA and prouPA vs. tPA monotherapy (historical comparison to GUSTO trial) was evaluated on Complete infarct artery opening rate (TIMI-3 patency).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: